ResearcherHospital Clínic de BarcelonaActive in the last 2 years
Leticia Moreira
Matched on ORCID iD 0000-0002-4518-8591; OpenAlex author ID A5048364982. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 0, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 25
2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 8
- Pancreatic cancer and biliary tract tumors in individuals with lynch syndrome. Co-author DOI 10.1016/j.dld.2025.09.025↗
- Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study. Last author DOI 10.3390/cancers16223779↗
- Pancreatic Cancer Surveillance in Carriers of a Germline Pathogenic Variant in CDKN2A. Last author DOI 10.3390/cancers15061690↗
- Familial Pancreatic Cancer: Current Perspectives. Last author DOI 10.2147/cmar.s172421↗
- Genetic Counseling for Hereditary Gastric and Pancreatic Cancer in High-Risk Gastrointestinal Cancer Clinics: An Effective Strategy. Last author DOI 10.3390/cancers12092386↗
- Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
- Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer. Co-author DOI 10.1016/j.jcmgh.2017.12.004↗
- [Hereditary gastric and pancreatic cancer predisposition syndromes]. Last author DOI 10.1016/j.gastrohep.2015.11.009↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Joan Llach · 4 shared papers, 2020–2024 · strength 0.59
- Paper Familial Pancreatic Cancer: Current Perspectives. DOI 10.2147/cmar.s172421↗
- Paper Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study. DOI 10.3390/cancers16223779↗
- Paper Pancreatic Cancer Surveillance in Carriers of a Germline Pathogenic Variant in CDKN2A. DOI 10.3390/cancers15061690↗
- Luís Bujanda · 2 shared papers, 2024–2025 · strength 0.38
- Marta Herreros‐Villanueva · 2 shared papers, 2024–2025 · strength 0.38
- Fabio Ausania · 2 shared papers, 2023–2024 · strength 0.31
- Julie Earl · 1 shared paper, 2024 · strength 0.16
- Maximilian Reichert · 2 shared papers, 2018 · strength 0.16
- Basil S. Bakir · 2 shared papers, 2018 · strength 0.16
- Glòria Fernández‐Esparrach · 1 shared paper, 2023 · strength 0.15
- Àngels Ginés · 1 shared paper, 2023 · strength 0.15
- Eva Cristina Vaquero · 1 shared paper, 2023 · strength 0.15
- Zahra Dantes · 1 shared paper, 2018 · strength 0.10
- Anil K. Rustgi · 1 shared paper, 2018 · strength 0.10
- Karin Feldmann · 1 shared paper, 2018 · strength 0.06
- Wilko Weichert · 1 shared paper, 2018 · strength 0.06
- Anna Melissa Schlitter · 1 shared paper, 2018 · strength 0.06
- Ravikanth Maddipati · 1 shared paper, 2018 · strength 0.06
- Volkan N. Adsay · 1 shared paper, 2018 · strength 0.06
- Kensuke Suzuki · 1 shared paper, 2018 · strength 0.06
- Günter Schneider · 1 shared paper, 2018 · strength 0.06
- Andrew D. Rhim · 1 shared paper, 2018 · strength 0.06
- Jason Robert Pitarresi · 1 shared paper, 2018 · strength 0.06
- Matthias Wirth · 1 shared paper, 2018 · strength 0.06
- Anil K. Rustgi · 1 shared paper, 2018 · strength 0.06
- Dieter Saur · 1 shared paper, 2018 · strength 0.06
- María Liz Leoz · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.